FIC20230032I1 - Pegunigalsidaasi alfa - Google Patents

Pegunigalsidaasi alfa

Info

Publication number
FIC20230032I1
FIC20230032I1 FIC20230032C FIC20230032C FIC20230032I1 FI C20230032 I1 FIC20230032 I1 FI C20230032I1 FI C20230032 C FIC20230032 C FI C20230032C FI C20230032 C FIC20230032 C FI C20230032C FI C20230032 I1 FIC20230032 I1 FI C20230032I1
Authority
FI
Finland
Prior art keywords
pegunigalsidase
alfa
pegunigalsidase alfa
Prior art date
Application number
FIC20230032C
Other languages
English (en)
Finnish (fi)
Original Assignee
Protalix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IL2010/000956 external-priority patent/WO2011061736A1/en
Application filed by Protalix Ltd filed Critical Protalix Ltd
Publication of FIC20230032I1 publication Critical patent/FIC20230032I1/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022Alpha-galactosidase (3.2.1.22)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
FIC20230032C 2010-03-02 2023-11-02 Pegunigalsidaasi alfa FIC20230032I1 (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30948710P 2010-03-02 2010-03-02
PCT/IL2010/000956 WO2011061736A1 (en) 2009-11-17 2010-11-17 Alkaline alpha galactosidase for the treatment of fabry disease
US201161434499P 2011-01-20 2011-01-20
US201161434503P 2011-01-20 2011-01-20

Publications (1)

Publication Number Publication Date
FIC20230032I1 true FIC20230032I1 (fi) 2023-11-02

Family

ID=44121635

Family Applications (1)

Application Number Title Priority Date Filing Date
FIC20230032C FIC20230032I1 (fi) 2010-03-02 2023-11-02 Pegunigalsidaasi alfa

Country Status (23)

Country Link
EP (3) EP2865751B1 (enExample)
JP (2) JP5758920B2 (enExample)
KR (1) KR101928403B1 (enExample)
CN (1) CN102933707B (enExample)
AU (1) AU2011222452B2 (enExample)
BR (2) BR112012022029B1 (enExample)
CA (1) CA2791461C (enExample)
DK (1) DK2865751T3 (enExample)
ES (2) ES2708843T3 (enExample)
FI (1) FIC20230032I1 (enExample)
FR (1) FR23C1041I2 (enExample)
HR (1) HRP20200428T1 (enExample)
HU (2) HUE030959T2 (enExample)
IL (2) IL221741A (enExample)
IN (1) IN2012MN02262A (enExample)
NL (1) NL301249I2 (enExample)
NO (1) NO2023041I1 (enExample)
NZ (2) NZ623294A (enExample)
PL (1) PL2865751T3 (enExample)
SG (2) SG183558A1 (enExample)
SI (1) SI2865751T1 (enExample)
WO (1) WO2011107990A1 (enExample)
ZA (1) ZA201206725B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
JP5758920B2 (ja) * 2010-03-02 2015-08-05 プロタリクス リミテッド 安定化α−ガラクトシダーゼおよびその使用
DK2665814T3 (en) * 2011-01-20 2017-09-11 Protalix Ltd NUCLEIC ACID CONSTRUCTION FOR EXPRESSION OF ALPHA-GALACTOSIDASE IN PLANTS AND PLANT CELLS
TW202332774A (zh) * 2013-10-23 2023-08-16 美商健臻公司 重組醣蛋白及其用途
AU2015370125B2 (en) 2014-12-22 2022-02-03 Codexis, Inc. Human alpha-galactosidase variants
WO2016116966A1 (en) * 2015-01-22 2016-07-28 Jcr Pharmaceuticals Co., Ltd. Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins
WO2016146760A1 (en) 2015-03-17 2016-09-22 Greenovation Biotech Gmbh Glycosylated lysosomal proteins, method of production and uses
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
CN110381987A (zh) * 2017-01-05 2019-10-25 波塔力克斯有限公司 使用稳定化α-半乳糖苷酶治疗法布里病的治疗方法
WO2018225623A1 (ja) * 2017-06-07 2018-12-13 天野エンザイム株式会社 ラクターゼ原末及びラクターゼ製剤
JP2022515742A (ja) 2018-12-20 2022-02-22 コデクシス, インコーポレイテッド α-ガラクトシダーゼバリアント
JP2023516301A (ja) * 2020-02-28 2023-04-19 コデクシス, インコーポレイテッド ヒトアルファ-ガラクトシダーゼ変異体
MX2023005235A (es) 2020-11-03 2023-10-16 Protalix Ltd Uricasa modificada y usos de la misma.
CN112176026A (zh) * 2020-11-06 2021-01-05 诺道中科(北京)生物科技有限公司 一种α-半乳糖苷酶活性的检测试剂盒
CN116254287B (zh) * 2022-11-24 2024-06-04 西北农林科技大学 玉米ZmAGA3基因用于提高植物耐旱性的应用
CN118243646B (zh) * 2024-04-24 2025-01-24 武汉简为医疗科技有限公司 一种乳糖不耐受检测试剂盒及其使用方法
JP7745040B1 (ja) * 2024-06-21 2025-09-26 デンカ株式会社 目的タンパク質の回収方法及び製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
CA2052728A1 (en) 1991-10-03 1993-04-04 Guy Ampleman Glycidyl azide polymer
US6329191B1 (en) * 1993-08-30 2001-12-11 Hawaii Biotechnology Group, Inc. DNA encoding recombinant coffee bean alpha-galactosidase
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US20050032211A1 (en) * 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
WO1999012959A1 (en) * 1997-09-05 1999-03-18 Altus Biologics Inc. Carbohydrate crosslinked glycoprotein crystals
IL125423A (en) 1998-07-20 2004-08-31 Israel State Alkaline alpha-galactosidase having broad substrate specificity
ATE303400T1 (de) * 1999-04-02 2005-09-15 Ajinomoto Kk Vefahren zur herstellung von peptiduntereinheiten aus polymer-proteinen
DK1523548T3 (da) 2002-05-15 2010-05-10 Agricultural Res Org Polynukleotidsekvenser, som koder for alkaliske alfa-galactosidaser, og fremgangsmåder til anvendelse heraf
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
JP5137814B2 (ja) * 2005-04-06 2013-02-06 ジェンザイム・コーポレーション 治療ターゲティングのための酸不安定リンカーを介するpegおよびポリシアルリソソーム酵素のコンジュゲート
EP1961816B1 (en) * 2005-11-18 2015-09-02 Tokyo Metropolitan Institute of Medical Science Novel highly functional enzyme having modified substrate-specificity
US20100144008A1 (en) 2006-12-21 2010-06-10 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Treatment of fabry disease
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
EP1955712A1 (en) * 2007-02-09 2008-08-13 Scil proteins GmbH Multimeric conjugate
BRPI0815324A2 (pt) 2007-08-20 2015-07-14 Protalix Ltd "conjugado protêico que contém sacarídeos, processo de separação do conjugado protêico que contém sacarídeos, composição farmacêutica do conjugado protêico que contém sacarídeos, uso do conjugado protêico que contém sacarídeos e composto do conjugado protêico que contém sacarídeos"
JP5758920B2 (ja) * 2010-03-02 2015-08-05 プロタリクス リミテッド 安定化α−ガラクトシダーゼおよびその使用

Also Published As

Publication number Publication date
PL2865751T3 (pl) 2017-03-31
BR112012022029B1 (pt) 2022-10-11
JP2013520986A (ja) 2013-06-10
SI2865751T1 (sl) 2017-01-31
KR101928403B1 (ko) 2018-12-14
AU2011222452B2 (en) 2015-09-03
NZ623294A (en) 2015-10-30
NL301249I2 (nl) 2023-12-14
HRP20200428T1 (hr) 2020-06-12
ES2708843T3 (es) 2019-04-11
FR23C1041I2 (fr) 2024-08-02
HK1180720A1 (en) 2013-10-25
ES2606532T3 (es) 2017-03-24
EP3088514A1 (en) 2016-11-02
JP5871999B2 (ja) 2016-03-01
CA2791461A1 (en) 2011-09-09
NO2023041I1 (no) 2023-11-01
DK2865751T3 (en) 2017-01-09
RU2012141651A (ru) 2014-04-10
IL221741A (en) 2017-07-31
IN2012MN02262A (enExample) 2015-06-12
EP2865751A1 (en) 2015-04-29
KR20130056216A (ko) 2013-05-29
JP2014237694A (ja) 2014-12-18
HUS2300038I1 (hu) 2023-11-28
NZ602317A (en) 2014-04-30
IL253249A (en) 2019-08-29
BR122014021216A2 (pt) 2021-06-01
CN102933707A (zh) 2013-02-13
EP2865751B1 (en) 2016-09-14
RU2604795C2 (ru) 2016-12-10
IL253249B (en) 2020-08-31
EP2542675B1 (en) 2014-12-17
AU2011222452A1 (en) 2012-09-27
JP5758920B2 (ja) 2015-08-05
HUE030959T2 (en) 2017-06-28
CA2791461C (en) 2019-10-22
FR23C1041I1 (enExample) 2023-12-29
NL301249I1 (enExample) 2023-11-08
EP2542675A1 (en) 2013-01-09
SG10201502609QA (en) 2015-05-28
SG183558A1 (en) 2012-10-30
WO2011107990A1 (en) 2011-09-09
BR112012022029A2 (pt) 2021-05-18
EP3088514B1 (en) 2018-11-28
ZA201206725B (en) 2013-06-26
CN102933707B (zh) 2015-09-30

Similar Documents

Publication Publication Date Title
FIC20230032I1 (fi) Pegunigalsidaasi alfa
FIC20220051I1 (fi) Olipudaasi alfa
FIC20240027I1 (fi) efbemalenograstiimi alfa
DK3225404T3 (da) Fluidpatron
EP2578585A4 (en) Purinone derivative
BR112012028556A2 (pt) Indóis
DE102011100241A8 (de) Nitridhalbleiterbauteil
CR20130111A (es) Triazina-oxidiazoles
DE10170954T8 (de) Mikrowellendruckgarer
EP2553434A4 (en) FLUOROMETRIC PROBE
EP2568873A4 (en) VACUUM RETRACTOR
EP2529782A4 (en) INTRODUCER SLEEVE ASSEMBLY
EP2591235A4 (en) FUSION METAL WHEEL
DE112011104226A5 (de) Käfigmutter
DE102011117046A8 (de) Doppelkupplungswindungsgetriebe
DE112011102080A5 (de) Kupplungszentralausrücker
DE112011101226A5 (de) Linearwegmesssystem
DK2539163T3 (da) Dækventil
DK2442899T3 (da) Rotorskive
DE102010038420A8 (de) Reinigungungsvorrichtung
NO2018032I1 (no) velmanase alfa
DE102011002623A8 (de) Ventilsteuerzeitversteller
EP2571003A4 (en) RISK CALCULATION APPARATUS
DE112011102711A5 (de) Hydrostataktor
DK2448659T3 (da) Rotorskive